<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34387">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658929</url>
  </required_header>
  <id_info>
    <org_study_id>CRB-401</org_study_id>
    <nct_id>NCT02658929</nct_id>
  </id_info>
  <brief_title>Study of bb2121 in Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>bluebird bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>bluebird bio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in
      adults with relapsed/refractory multiple myeloma (MM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A of the study will enroll adults with multiple myeloma using a 3+3 dose escalation
      approach. An expansion cohort will be enrolled following dose selection.

      Following consent, enrolled subjects will undergo a leukapheresis procedure to collect
      autologous mononuclear cells for manufacture of investigational drug product (bb2121).
      Following manufacture of the drug product, subjects will receive lymphodepletion prior to
      bb2121 infusion. All subjects will then be followed for up to 24 months in Study CRB-401.

      All subjects who complete the study, as well as those who withdraw from the study after
      receiving bb2121 for reasons other than death or meeting the early termination criteria,
      will be asked to continue to undergo long-term follow-up in a companion study LTF-305 for up
      to 15 years after their last bb2121 infusion, with a focus on long-term safety and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and abnormal laboratory test results, including dose limiting toxicities (DLTs)</measure>
    <time_frame>Day 1 through Month 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-specific response criteria including: complete response (CR), very good partial response (VGPR), and partial response (PR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma</measure>
    <time_frame>Month 1 through Month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>bb2121 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bb2121</intervention_name>
    <arm_group_label>bb2121 Experimental Arm</arm_group_label>
    <other_name>autologous T cells transduced ex-vivo with anti-BCMA02 CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 years of age at the time of signing informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Diagnosis of MM with relapsed or refractory disease and have had at least 3 different
             prior lines of therapy including proteasome inhibitor (e.g., bortezomib or
             carfilzomib) and immunomodulatory therapy (IMiD; e.g., lenalidomide or pomalidomide),
             or have &quot;double refractory&quot; disease to a proteasome inhibitor and IMiD, defined as
             progression on or within 60 days of treatment with these agents.

          -  Subjects must have measurable disease

          -  Women of child-bearing potential (WCBP) must have a negative serum pregnancy test
             prior to treatment. All sexually active WCBP and all sexually active male subjects
             must agree to use effective methods of birth control throughout the study

        Exclusion Criteria:

          -  Subjects with known central nervous system disease

          -  Inadequate hepatic function

          -  Inadequate renal function

          -  Inadequate bone marrow function

          -  Presence of active infection within 72 hours

          -  Subjects with a history of stroke, unstable angina, myocardial infarction, or
             ventricular arrhythmia requiring medication or mechanical control

          -  Significant co-morbid condition or disease which in the judgment of the Investigator
             would place the subject at undue risk or interfere with the study; examples include,
             but are not limited to, cirrhotic liver disease, sepsis, recent significant traumatic
             injury, and other conditions

          -  Known human immunodeficiency virus (HIV) positivity

          -  Subjects with a history of stroke, unstable angina, myocardial infarction, or
             ventricular arrhythmia requiring medication or mechanical control

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>bluebird bio</last_name>
    <email>clinicaltrials@bluebirdbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reneth Tien</last_name>
      <phone>650-723-0646</phone>
      <email>rtien@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Uzma Ahmed</last_name>
      <phone>650-723-0670</phone>
      <email>uzma.ahmed@stanford.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Lawrence</last_name>
      <phone>301-827-0022</phone>
      <email>judith.lawrence@nih.gov</email>
    </contact>
    <contact_backup>
      <last_name>Brenna Hansen</last_name>
      <phone>301-435-5605</phone>
      <email>hansenb3@mail.nih.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Munshi, MD</last_name>
      <phone>617-632-5607</phone>
      <email>nikil_munshi@dfci.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robert Schlossman, MD</last_name>
      <phone>617-632-5126</phone>
      <email>Robert_Schlossman@dfci.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noopur Raje</last_name>
      <phone>617-724-4000</phone>
      <email>nraje@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacalyn Rosenblatt, MD</last_name>
      <phone>617-667-9920</phone>
      <email>jrosenb1@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayo Clinic Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura McBride</last_name>
      <email>lmcbride@hackensackumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa La</last_name>
      <phone>212-241-8615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Sindler, RN</last_name>
      <phone>615-335-0190</phone>
      <email>Melissa.sindler@scresearch.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>January 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
